OBJECTIVE: To obtain an appraisal for the use of methylprednisolone (MP) in the early
management of acute spinal cord injury (SCI) in our health system and the attitude to its use …

BACKGROUND CONTEXT: Methylprednisolone has evolved during the 1990s, through the
results obtained from the National Acute Spinal Cord Injury Studies NASCIS II and III, as a …

Background: A systematic review of the evidence pertaining to methylprednisolone infusion
following acute spinal cord injury was conducted in order to address the persistent confusion …

Object. Since publication in 1990, results from the National Acute Spinal Cord Injury Study II
(NASCIS II) trial have changed the way patients suffering an acute spinal cord injury (SCI) …

80. Trauma in the West of Ireland, June 1996 to July 2001 — an audit 81. Methylprednisolone in
acute spinal cord injuries — Page 1 27th Sir Peter Freyer Memorial Lecture 2002 in association …

Background Methylprednisolone is the only neuroprotective therapy advocated in acute non-
penetrating spinal cord injury. Trials indicate improved neurological outcome following early …

High doses of methylprednisolone (MPSS) came into use as part of a therapeutic protocol
for acute spinal cord injuries following the published results from the NASCIS II study in …

Ever since the publication in 1990 in The New England Journal of Medicine of a multicentre,
randomised, double-blind, placebo-controlled trial on the efficacy of methylprednisolone …

Study design: Systematic literature review for primary data using predefined inclusion,
exclusion and validity criteria. Primary outcome measure was standardised neurological …

Objective: To re-evaluate practice patterns for methylprednisolone (MP) administration in
patients with acute spinal cord injury (SCI) within the spinal surgery community across …